How Novartis is Changing Cancer Treatment and Putting Patients First in Modern Cancer Care
In this episode of "Rx for Biotech", host Chris Leidli speaks with Rodney Gillespie, Senior Vice President and U.S. Therapeutic Area Head for Oncology at Novartis, about the rapid evolution of prostate cancer care, including the rise of radioligand therapy and PSMA-targeted treatments like Pluvicto® (lutetium Lu 177 vipivotide tetraxetan). We discuss: * How PSMA-targeted radioligand therapy delivers radiation directly to cancer cells * The role of innovation in advanced and metastatic prostate cancer * Expanding patient access to cutting-edge therapies * Why patient advocacy and education…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.